Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Revenue of Roivant Sciences Ltd. (ROIV)
Revenue in 2023 (TTM): $124.8 M
According to Roivant Sciences Ltd.'s latest financial reports the company's current revenue (TTM) is $124.8 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Roivant Sciences Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $124.8 M | $109.24 M | $4.31 B | $4.25 B | $4.35 B |
| 2022 | $61.28 M | $48.15 M | $-1,178,009,000 | $-1,224,834,000 | $-1,009,030,000 |
| 2021 | $55.29 M | $46.32 M | $-916,705,999 | $-923,747,000 | $-845,262,000 |
| 2020 | $23.8 M | $21.74 M | $-895,737,999 | $-898,547,000 | $-809,234,000 |
| 2019 | $67.69 M | $66.56 M | $-553,302,999 | $-560,986,000 | $1.2 B |